DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "OpportunityAnalyzer: Glioblastoma - Opportunity Analysis and Forecasts to 2024" report to their offering.
Glioblastoma multiforme (GBM) is characterized as a disease with some of the highest unmet needs in oncology, with patients having a median overall survival (OS) of between one and two years. The lack of therapies is primarily due to the inability of drugs to penetrate the blood-brain barrier (BBB). The GBM market is currently dominated by temozolomide and Avastin which are considered as standards of care in newly diagnosed and recurrent settings, respectively.
Between 2014 and 2024, the market is set to undergo substantial growth due to a number companies developing therapies in the late-stage pipeline, which is dominated by immunotherapies. On one hand, the main drivers of growth will be the launch of EGFR-targeting therapies such as Rintega and ABT-414, as well as the checkpoint inhibitor Opdivo.
Furthermore, the launch of autologous cell vaccines such as ICT-107 and DCVax-L will also impact the GBM market. On the other hand, the GBM market constrainers remain modest with the increasing cost-consciousness of healthcare providers, and the launch of biosimilar bevacizumab in the 7MM (US, France, Germany, Italy, Spain, UK and Japan).
Key Questions Answered
- The GBM market is marked by the presence of a number of unmet needs. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of GBM market?
- The late-stage GBM pipeline has therapies targeting different GBM populations. Which late-stage drugs will have the biggest impact in each patient population? Which of these drugs will have the highest peak sales at the highest CAGR, and why?
- Current therapies used to treat GBM include temozolomide, Gliadel and Avastin. How will the advent of new therapies change the drug treatment landscape for GBM? How will the drug treatment rate change over the next five years? What are the key drivers and barriers to this change?
- The main driver of the enormous expansion of the GBM market will be the launch of Opdivo for newly diagnosed and recurrent GBM. GlobalData forecasts significant patient uptake for Opdivo which will supersede Avastin to become the SoC in the recurrent setting.
- The second largest driver will be the launch of Rintega for EGFRvIII positive GBM. Rintega uptake would be partially facilitated by the availability of EGFRvIII companion diagnostics, which help to identify patients most likely to respond to the treatment.
- The approval of Rintega and Opdivo will partially fulfil key unmet needs in the GBM space: however, many of these unmet needs will still remain even after these agents are launched.
- Another driver of the GBM market is the increasing incidence of GBM cases within the 7MM. The biggest constrainer of the GBM market is the launch of biosimilar bevacizumab in the 7MM.
- Arbor Pharmaceuticals
- Boehringer Ingelheim
- Bristol-Myers Squibb Company
- Celldex Therapeutics
- Immunocellular Therapeutics
- Merck & Co.
- Northwest Biotherapeutics
- Ono Pharmaceuticals
- Peregrine Pharmaceuticals
- TVAX Biomedical
- VBL Therapeutics
For more information visit http://www.researchandmarkets.com/research/jnjc2m/opportunityanalyze